GTM-W5BPZ85
Skip to main content
  1. Home >
  2. About Fujitsu >
  3. Resources >
  4. News >
  5. Press releases >
  6. 2019 >
  7. Fujitsu Applies Innovative AI Text Mining to Automate Medical Notes Coding

Fujitsu Applies Innovative AI Text Mining to Automate Medical Notes Coding

Fujitsu EMEIA

News facts:
  • Fujitsu Laboratories of Europe has developed an innovative AI-based technology to automate the medical coding of non-structured medical texts
  • By automating the process of clinical notes’ annotation, medical professionals gain access to patient information faster, freeing up their time to focus on patient care
  • The state-of-the-art AI solution deploys text mining techniques and reduces the time required for medical coding tasks by over 90%
London, July 04, 2019 – At the annual Fujitsu Innovation Gathering today in London, Fujitsu Laboratories of Europe today announces a new AI technology that enhances Electronic Health Record (EHR) management, automating the processing of unstructured (free text) medical notes and achieving time savings of more than 90% with significantly improved accuracy. Ensuring compliance with mandatory medical classifications, Fujitsu’s new automatic medical coding solution extracts the annotations in typically less than 1 minute, compared to 15 minutes required for manual clinical note annotation. Unlike previous generation technologies, Fujitsu’s AI text mining technology combines semantic knowledge and Natural Language Processing (NLP) with Deep Learning in order to analyze medical notes and extract valuable data.
Fujitsu Laboratories of Europe works closely with innovation partners within the healthcare sector, including Madrid’s leading San Carlos Clinical Hospital, working on a variety of successful clinical projects in the past 4 years. Dr Julio Mayol, Chief Medical Officer, explains the importance of this co-creation approach from a medical perspective, “We are constantly looking for new ways of improving clinical decision-making, and our work with Fujitsu Laboratories of Europe is helping us to realize important advances to improve efficiency. Most of the EHR systems available today do not fulfil the requirements of the doctor/patient relationship. In fact, the use of EHR has been directly associated to clinician burn-out, as demonstrated by a number of studies. With new technologies such as Fujitsu’s latest AI text mining technology, we can address these challenges directly, and achieve tangible improvements to the clinical decision-making process.”
Fujitsu Laboratories of Europe’s Chief Executive Officer Dr Adel Rouz expands, “Our co-creation strategy with partners such as the San Carlos Clinical Hospital has provided us with an important insight into the challenges faced by the healthcare sector, particularly in terms of supporting clinical decision-making. We have succeeded in creating a number of important innovations that are already making a difference to medical professionals’ workflow. This latest advance is another step, helping to improve the accuracy of clinical data and automate its digitalization for hospitals, medical insurance companies and government agencies. We believe that our technology has wider applications and can easily be adapted to solve similar challenges in other domains, such as insurance, legal and compliance.”
Structured information plays an essential role in medical decision-making and improving healthcare delivery. However, as clinicians are faced with significantly less direct patient time, the requirement for immediate data entry onto EHR systems represents a major additional burden. By enabling more flexible data entry methods, such as free text narrative associated with a patient report, this overhead can be reduced while also allowing clinicians to record more useful and appropriate patient data. Using its proven NLP techniques, Fujitsu Laboratories and Fujitsu Laboratories of Europe’s collaborated solution directly addresses this need, automatically extracting the structured information required by the EHR system from clinicians’ free narrative text. Using deep learning, the solution can be retrained to match a clinician’s individual needs, enabling additional flexibility compared to the limitations associated with complex linguistic rules used by many existing codification systems in order to identify the correct terms from the free text. The result is a high degree of accuracy, matched by the ability to extract a wider cross-section of relevant terms than just International Statistical Classification of Diseases and Related Health Problems (ICD) codes, relating to treatment adherence or social background data.
Fujitsu’s AI Text Mining healthcare solution exploits text mining together with Deep Learning techniques in concrete steps of the medical coding workflow, avoiding the dependency on huge pre-annotated datasets. Fujitsu’s approach comprises two key components:
  • creation of the knowledge base: a knowledge graph is designed to depict the medical classifications and enriched semantically with external resources. This semantic enrichment provides additional context to medical classifications, translating into improved results in the successive stages of the process. Ontologies and word embedding techniques are used for the semantic enrichment.
  • recognition and assignment: involving a medical terms‘ recognition process using Deep Learning, followed by the definition of weighted score-ranking formulas to calculate the potential encoding of input clinical notes.

Figure: Fujitsu’s AI Text Mining Healthcare process for automatic medical coding
Fujitsu’s AI technology was evaluated across two English language datasets, involving 200 private anonymized clinical notes, and 5000 discharge summaries extracted from MIMIC-III resource1. An additional benefit of Fujitsu’s technology is that it is easily adaptable to any medical classification or to other languages, and does not require huge pre-annotated datasets.
By improving the accuracy and precision of the medical coding process, Fujitsu’s technology contributes to the realization of standardized outcomes, and delivers time-savings for professionals. The processed and annotated information is used for policy planning by government agencies, medical research to improve medical treatment, price setting by insurance companies, as well as diagnosis and treatment by clinicians. Fujitsu’s new solution will be applied to the ongoing collaborative research program with the San Carlos Innovation Centre during 2019.
Notes :
1MIMIC-III1 is a publicly available clinical database and a current reference/gold standard for the benchmarking of these types of problem in the Healthcare community. MIMIC-III comprises de-identified health-related data of the Critical Care Units of the Beth Israel Deaconess Medical Center between 2001 and 2012. This includes a wide range of data such as demographics, vital sign measurements, laboratory tests, clinical notes, etc.

Online resources

About Fujitsu

Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 132,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.0 trillion yen (US $36 billion) for the fiscal year ended March 31, 2019. For more information, please see www.fujitsu.com.

About Fujitsu Laboratories of Europe

Established in 2001 and with an active presence in Europe since 1990, Fujitsu Laboratories of Europe Limited represents Fujitsu Laboratories across EMEIA, focused on the creation of cutting-edge innovations that benefit society and business. By adopting a co-creation strategy and working with customers and collaboration partners, its extensive R&D and co-creation activities span Artificial Intelligence, Trusted Technologies, AI Ethics, Blockchain, Cyber Security, Approximate Computing and Digital Annealer applications. Fujitsu Laboratories of Europe is considered one of the leading research and development centers in EMEIA, with its wide range of R&D and co-creation activities focusing on cutting edge innovations that address real-world challenges, underpinned by ethical concepts. For more information, please see http://www.fujitsu.com/uk/fle/.

Media Contacts

Georgina Garrett
Director
Garrett Axford Ltd (on behalf of Fujitsu Laboratories of Europe Ltd)

Phone: Phone: +44 7778 216004
E-mail: E-mail: fujitsu@garrett-axford.co.uk


All other company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.

Date: 04 July, 2019
City: London